Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: Investigation from the United States food and drug administration adverse event reporting system database

Pharmacotherapy

Volumn 32, Issue 10, 2012, Pages 902-909

  Gandhi, Pranav K ^a   Gentry, William M ^a   Bottorff, Michael B ^a  

^a South College School of Pharmacy   (United States)

Author keywords

Adverse event reporting system database; C1 esterase inhibitor; Food and Drug Administration; HAE; Hereditary angioedema; Thrombotic events

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; BLINDNESS; CAUSAL ATTRIBUTION; CHILD; CLINICAL EFFECTIVENESS; DEEP VEIN THROMBOSIS; DEVICE INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENITIS; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HEART INFARCTION; HUMAN; HYPOTENSION; ILEUS; INFUSION RELATED REACTION; INTRACARDIAC THROMBOSIS; ISCHEMIC COLITIS; LACTIC ACIDOSIS; LIMB PAIN; LUNG EMBOLISM; MALE; MIGRAINE; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL EDEMA; REFERENCE DATABASE; RETROSPECTIVE STUDY; SCHOOL CHILD; SUPRAVENTRICULAR TACHYCARDIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANGIOEDEMAS, HEREDITARY; BAYES THEOREM; CHILD; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1S; COMPLEMENT INACTIVATING AGENTS; DATA MINING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PEPTIDES; RETROSPECTIVE STUDIES; THROMBOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84867289618     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01126     Document Type: Article

References (28)

1. Zuraw BL. Hereditary angioedema. N Engl J Med 2008;359:1027-36.
2. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Invest Drugs 2006;15:1077-90.
3. Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol 2005;114:3-9.
4. Zuraw BL. HAE therapies: past, present and future. Allergy Asthma Clin Immunol 2010;6:23.
5. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Asthma Immunol 2008;100:S30-40.
6. Bork K, Guel D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007;120:987-92.
7. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24.
8. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009;124:129-34.
9. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74.
10. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992;72:206-15.
11. Sardana N, Craig T. Recent advances in management and treatment of hereditary angioedema. Periatrics 2011;128:1173-80.
12. Lev Pharmaceuticals, Inc. Cinryze (C1 esterase inhibitor [human]) package insert. New York, NY; 2008. Available from http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/UCM129918. Accessed January 18, 2012.
13. CSL Behring GmbH. Berinert. (C1 esterase inhibitor [human]) package insert. Marburg, Germany; 2009.
14. Dyax Corporation. Kalbitor (DX-88 [ecallantide]) package insert. Cambridge, MA; 2009.
15. Shire. Firazyr (icatibant) pakage insert. Wayne, PA; 2011. Available from http://pi.shirecontent.com/PI/PDFs/Firazyr-USA- ENG.pdf. Accessed January 18, 2012.
16. Toscani M, Riedl M. Meeting the challenges and burdens associated with hereditary angioedema. Manag Care 2011;20:44-51.
17. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Ecallantide (DX-88) for acute hereditary angioedema: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 2011;128:153-9.
18. U.S. Food and Drug Administration. Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS) between January-March 2010. Available from http://www.fda.gov/Drugs/ GuidanceCompliance RegulatoryInformation/Surveillance/AdverseDrugEffects/ucm 216272.htm. Accessed March 2, 2012.
19. Piccinni C, Marchesini G, Motola G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-71.
20. U.S. Food and Drug Administration. The Adverse Event Reporting System (AERS) latest quarterly data files. Available from http://www.fda.gov/cder/aers/ extract.htm. Accessed January 18, 2012.
21. Hauben M, Reich L, Gerrits CM. Reports of hyperkalemia after publication of RALES - a pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006;15:775-83.
22. van Puijenbroek EP, Bate A, Leufkens HGM, Lidquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11:3-10.
23. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54(4):315-21.
24. Noren GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med 2006;25:3740-57.
25. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RHB. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO International Database. Drug Saf 2000;23(6):533- 42.
26. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005;4(5):929-48.
27. Ratcliffe S, Younus M, Hauben M, Reich L. Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spontaneous reporting of cardiomyopathy. J Psychopharmacol 2010;24:503-11.
28. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007;30(5):367-73.